RetiSpec and Toronto Memory Program are one of twelve select recipients of the inaugural grant for early detection of Alzheimer’s disease by the Davos Alzheimer’s Collaborative (DAC), the organization leading global response to Alzheimer’s. The DAC grants are an initiative to advance efforts towards the detection, diagnosis, and treatment for people with or at risk of Alzheimer’s.
RetiSpec, in collaboration with the Toronto Memory Program and the Alzheimer Societies of Ontario and Toronto, announced a unique project to screen for Alzheimer’s disease in community settings. The project implements the world’s first screening model based on the collaboration between optometry and a local Alzheimer Society to identify individuals at risk for Alzheimer’s disease.
About RetiSpec
Retispec is a Toronto-based artificial intelligence (AI) medical imaging company developing tools for the early detection of disease biomarkers in the eye. Retispec believes that a better future for Alzheimer's starts with the ability to diagnose it. With its unique technology, Retispec’s mission is to enable widespread early and accurate detection of neurodegenerative disease markers, with accessible, affordable, and scalable retinal screening.
RetiSpec in an OBIO® member.